Literature DB >> 15003504

CD43 has a functional NLS, interacts with beta-catenin, and affects gene expression.

Christian X Andersson1, Julia Fernandez-Rodriguez, Sirle Laos, Rein Sikut, Anu Sikut, Dan Baeckström, Gunnar C Hansson.   

Abstract

CD43 is a transmembrane molecule with a highly O-glycosylated extracellular domain of mucin type. It is a normal constituent of leukocytes and found in colon adenoma, but not in normal colon epithelia. Here it is shown that the cytoplasmic tail of CD43 contains a functional bipartite nuclear localization signal directing it to the nucleus. The intracellular domain of CD43 interacts with beta-catenin and causes an upregulation of the beta-catenin target genes c-MYC and CyclinD1. The present results suggest that CD43 can be involved in nuclear signaling and via beta-catenin interaction be involved in cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15003504     DOI: 10.1016/j.bbrc.2004.02.011

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

1.  The cleavage of neutrophil leukosialin (CD43) by cathepsin G releases its extracellular domain and triggers its intramembrane proteolysis by presenilin/gamma-secretase.

Authors:  Agnès Mambole; Dominique Baruch; Patrick Nusbaum; Sylvain Bigot; Misa Suzuki; Philippe Lesavre; Minoru Fukuda; Lise Halbwachs-Mecarelli
Journal:  J Biol Chem       Date:  2008-06-27       Impact factor: 5.157

Review 2.  The many substrates of presenilin/γ-secretase.

Authors:  Annakaisa Haapasalo; Dora M Kovacs
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

3.  Presenilin/gamma-secretase and alpha-secretase-like peptidases cleave human MHC Class I proteins.

Authors:  Bryce W Carey; Doo Y Kim; Dora M Kovacs
Journal:  Biochem J       Date:  2007-01-01       Impact factor: 3.857

Review 4.  Trafficking of receptor tyrosine kinases to the nucleus.

Authors:  Graham Carpenter; Hong-Jun Liao
Journal:  Exp Cell Res       Date:  2008-10-11       Impact factor: 3.905

5.  An alternative mode of CD43 signal transduction activates pro-survival pathways of T lymphocytes.

Authors:  Maria Elena Bravo-Adame; Rosario Vera-Estrella; Bronwyn J Barkla; Cecilia Martínez-Campos; Angel Flores-Alcantar; Jose Pablo Ocelotl-Oviedo; Gustavo Pedraza-Alva; Yvonne Rosenstein
Journal:  Immunology       Date:  2016-10-12       Impact factor: 7.397

6.  Shedding and gamma-secretase-mediated intramembrane proteolysis of the mucin-type molecule CD43.

Authors:  Christian X Andersson; Julia Fernandez-Rodriguez; Sirle Laos; Dan Baeckström; Christian Haass; Gunnar C Hansson
Journal:  Biochem J       Date:  2005-04-15       Impact factor: 3.857

7.  CD43 interaction with ezrin-radixin-moesin (ERM) proteins regulates T-cell trafficking and CD43 phosphorylation.

Authors:  J L Cannon; P D Mody; K M Blaine; E J Chen; A D Nelson; L J Sayles; T V Moore; B S Clay; N O Dulin; R A Shilling; J K Burkhardt; A I Sperling
Journal:  Mol Biol Cell       Date:  2011-02-02       Impact factor: 4.138

Review 8.  Aberrant glycosylation as biomarker for cancer: focus on CD43.

Authors:  Franca Maria Tuccillo; Annamaria de Laurentiis; Camillo Palmieri; Giuseppe Fiume; Patrizia Bonelli; Antonella Borrelli; Pierfrancesco Tassone; Iris Scala; Franco Maria Buonaguro; Ileana Quinto; Giuseppe Scala
Journal:  Biomed Res Int       Date:  2014-02-13       Impact factor: 3.411

9.  Intracellular patterns of sialophorin expression define a new molecular classification of breast cancer and represent new targets for therapy.

Authors:  Q Fu; S E Cash; J J Andersen; C R Kennedy; A R Madadi; M Raghavendra; L L Dietrich; W A Agger; C S Shelley
Journal:  Br J Cancer       Date:  2013-11-26       Impact factor: 7.640

10.  CD43 promotes cells transformation by preventing merlin-mediated contact inhibition of growth.

Authors:  Nohemi Camacho-Concha; Amiel Olivos-Ortiz; Alfredo Nuñez-Rivera; Adolfo Pedroza-Saavedra; Lourdes Gutierrez-Xicotencatl; Yvonne Rosenstein; Gustavo Pedraza-Alva
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.